A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) (NCT07549412)
🩺 Plain-English Summary (8th-Grade Level)
This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocentecan (Precem-TcT) as single agent or Precem-TcT in combination with bevacizumab compared to trifluoride/tipiracil (FTD-TPI) plus bevacizumab.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (7 items).
Location: Rocky Mountain Cancer Centers, LLP- Aurora — Lone Tree, Colorado
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- If Adverse Events related to previous therapies have not recovered to less than Grade 1 by National Cancer Institute - Common Terminology Criteria for Adverse Events version 6.0
- Participant has a history of additional malignancy within 3 years before randomization
- Participants with known brain metastases
- Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months prior to randomization
- Participants with ileus of more than Grade 1, or chronic inflammatory bowel disease (example ulcerative colitis, Crohn's disease) and/or bowel obstruction, or participants with chronic gastrointestinal disorders that, in the Investigator's opinion, might significantly interfere with proper absorption of the study treatments
- Other protocol defined exclusion criteria may apply
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (34 Sites)
- Rocky Mountain Cancer Centers, LLP- Aurora — Lone Tree, Colorado
- Florida Cancer Specialists-Broadway — Fort Myers, Florida
- Florida Cancer Specialists - St. Petersburg Bayfront — St. Petersburg, Florida
- Florida Cancer Specialists East - FCS EAST - West Palm Beach — West Palm Beach, Florida
- Illinois Cancer Specialists — Arlington Heights, Illinois
- Illinois CancerCare PC — Peoria, Illinois
- Springfield Clinic — Springfield, Illinois
- Profound Research LLC at Cancer and Leukemia Center — Sterling Heights, Michigan
- Minnesota Oncology Hematology, P.A. — Saint Louis Park, Minnesota
- Missouri Cancer Associates - 150518964 — Columbia, Missouri
- SCRI Oncology Partners — Nashville, Tennessee
- Texas Oncology, P.A. - Abilene - 300210366 — Abilene, Texas
- Texas Oncology-South Austin — Austin, Texas
- Texas Oncology DFW — Bedford, Texas
- Texas Oncology- San Antonio — San Antonio, Texas
- Texas Oncology, P.A. - Tyler — Tyler, Texas
- Virginia Oncology Associates — Newport News, Virginia
- Blue Ridge Cancer Care - 300202915 — Roanoke, Virginia
- GenesisCare North Shore (Oncology) — St Leonards, New South Wales
- Icon Cancer Centre Chermside — Chermside, Queensland
- Mater Misericordiae Ltd - PARENT — South Brisbane, Queensland
- Flinders Medical Centre — Bedford Park, South Australia
- University Health Network - Princess Margaret Cancer Centre — Toronto, Ontario
- Sun Yat-sen University Cancer Center — Guangzhou, Guangdong
- Sichuan Cancer Hospital — Chengdu, Sichuan
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.